

Title (en)

TREATMENT OF MOOD/AFFECTIVE DISORDERS BY GLUTAMATERGIC UPMODULATORS

Title (de)

BEHANDLUNG VON GEMÜTS-UND LAUNEKRANKHEITEN MIT GLUTAMATERGISCHEN MODULATOREN.

Title (fr)

TRAITEMENT DES TROUBLES DE L'HUMEUR ET DES TROUBLES AFFECTIFS PAR DES RENFORATEURS GLUTAMATERGIQUES

Publication

**EP 0918518 A4 20020502 (EN)**

Application

**EP 97906793 A 19970227**

Priority

- US 9703121 W 19970227
- US 63508896 A 19960419

Abstract (en)

[origin: WO9739750A1] Affective disorders in humans are treated by enhancing glutamatergic transmission. This is achieved in various ways, one of which is by the administration of a class of therapeutic agents having a phenyl ketone-containing molecular structure and similar to the structure of aniracetam. This discovery is based on tests using REM sleep reduction in an animal model as an indicator.

IPC 1-7

**A61K 31/335; A61K 31/36; A61K 31/40; A61K 31/415; A61K 31/42; A61K 31/44; A61K 31/445; A61K 31/495; A61K 31/50; A61K 31/535; A61K 31/55**

IPC 8 full level

**A61K 31/00 (2006.01); A61K 31/138 (2006.01); A61K 31/15 (2006.01); A61K 31/36 (2006.01); A61K 31/4015 (2006.01); A61K 31/4025 (2006.01); A61K 31/44 (2006.01); A61K 31/4406 (2006.01); A61K 31/443 (2006.01); A61K 31/4433 (2006.01); A61K 31/4439 (2006.01); A61K 31/4453 (2006.01); A61K 31/4525 (2006.01); A61K 31/454 (2006.01); A61K 31/498 (2006.01); A61K 31/4985 (2006.01); A61K 31/5365 (2006.01); A61K 31/55 (2006.01)**

CPC (source: EP)

**A61K 31/00 (2013.01); A61K 31/138 (2013.01); A61K 31/15 (2013.01); A61K 31/36 (2013.01); A61K 31/4015 (2013.01); A61K 31/4025 (2013.01); A61K 31/44 (2013.01); A61K 31/4406 (2013.01); A61K 31/443 (2013.01); A61K 31/4433 (2013.01); A61K 31/4439 (2013.01); A61K 31/4453 (2013.01); A61K 31/4525 (2013.01); A61K 31/454 (2013.01); A61K 31/498 (2013.01); A61K 31/4985 (2013.01); A61K 31/5365 (2013.01); A61K 31/55 (2013.01)**

Citation (search report)

- [X] US 3917617 A 19751104 - RAZDAN RAJ KUMAR, et al
- [X] FR 3080 M 19650125 - GUIDOTTI & C SA LAB [IT]
- [PX] WO 9638414 A1 19961205 - CORTEX PHARMA INC [US]
- [X] US 4013768 A 19770322 - FAURAN CLAUDE P, et al
- [X] US 5434169 A 19950718 - JEGHAM SAMIR [FR], et al
- [X] US 4061855 A 19771206 - FAURAN CLAUDE P, et al
- [X] US 5459138 A 19951017 - PIROTTE BERNARD [BE], et al
- [A] US 4461906 A 19840724 - ASCHWANDEN WERNER [CH], et al
- [A] WO 9402475 A1 19940203 - UNIV CALIFORNIA [US], et al
- [A] US 4186135 A 19800129 - ACHER JACQUES [FR], et al
- [X] DO, GYONG SAM ET AL: "Syntheses and central nervous depressant activities of piperidine derivatives (V). Methylenedioxyphenyl alkenoic acid amides", YAKHAK HOECHI (1986), 30(4), 163-8, XP000989504
- [X] CICARDO, V. H. ET AL: "Effects of aniracetam on GABAergic-monoaminergic systems in rat brain and on motility: interaction with antagonists of dopamine receptors", IRCS MED. SCI. ( 1986 ), 14(11), 1081-2, XP000986720
- [A] STANCHEVA S L ET AL: "EFFECTS OF CENTROPHENOXINE PYRACETAM AND ANIRACETAM ON MONOAMINE OXIDASE ACTIVITY IN DIFFERENT RAT BRAIN STRUCTURES.", FARMAKOL TOKSIKOL (MOSC), (1988) 51 (3), 16-18., XP000986483
- [X] SALETU B ET AL: "QUANTITATIVE EEG AND PSYCHOMETRIC ANALYSES IN ASSESSING CNS-ACTIVITY OF RO 13-5057 - A CEREBRAL INSUFFICIENCY IMPROVER", METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY,ES,PROUS, BARCELONA, vol. 2, no. 5, 1980, pages 269 - 285, XP000905198, ISSN: 0379-0355
- See references of WO 9739750A1

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

**WO 9739750 A1 19971030; AU 2139497 A 19971112; AU 714477 B2 20000106; CA 2250856 A1 19971030; EP 0918518 A1 19990602; EP 0918518 A4 20020502**

DOCDB simple family (application)

**US 9703121 W 19970227; AU 2139497 A 19970227; CA 2250856 A 19970227; EP 97906793 A 19970227**